Pfizer Settles Patent Lawsuits with Generic Drug Makers
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy PFE?
Source: Newsfilter
- Settlement Agreements: Pfizer has entered into settlement agreements with Dexcel Pharma, Hikma Pharmaceuticals, and Cipla Ltd, extending the patent expiry date for VYNDAMAX to June 1, 2031, which stabilizes expected revenues and mitigates the anticipated decline starting in 2029.
- Market Leadership: VYNDAMAX commands a 75% share of the ATTR-CM prescription market, being the only once-daily capsule approved for this condition, demonstrating significant reductions in all-cause mortality and cardiovascular-related hospitalizations, thereby reinforcing Pfizer's competitive edge.
- Enhanced Patient Care: Pfizer's decision to discontinue VYNDAQEL in the U.S. focuses on VYNDAMAX, aiming to improve patient convenience and adherence through a single daily capsule, particularly beneficial for patients with multiple concurrent conditions requiring various oral medications.
- Commitment to Innovation: Pfizer executives highlighted that the settlement outcome not only recognizes the value of innovative science but also underscores the company's unwavering commitment to ATTR-CM patients, which is expected to further enhance VYNDAMAX's market penetration and patient reach.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 26.790
Low
24.00
Averages
28.56
High
35.00
Current: 26.790
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pfizer Settles Patent Lawsuits with Generic Drug Makers
- Settlement Agreements: Pfizer has entered into settlement agreements with Dexcel Pharma, Hikma Pharmaceuticals, and Cipla Ltd, extending the patent expiry date for VYNDAMAX to June 1, 2031, which stabilizes expected revenues and mitigates the anticipated decline starting in 2029.
- Market Leadership: VYNDAMAX commands a 75% share of the ATTR-CM prescription market, being the only once-daily capsule approved for this condition, demonstrating significant reductions in all-cause mortality and cardiovascular-related hospitalizations, thereby reinforcing Pfizer's competitive edge.
- Enhanced Patient Care: Pfizer's decision to discontinue VYNDAQEL in the U.S. focuses on VYNDAMAX, aiming to improve patient convenience and adherence through a single daily capsule, particularly beneficial for patients with multiple concurrent conditions requiring various oral medications.
- Commitment to Innovation: Pfizer executives highlighted that the settlement outcome not only recognizes the value of innovative science but also underscores the company's unwavering commitment to ATTR-CM patients, which is expected to further enhance VYNDAMAX's market penetration and patient reach.
See More
BridgeBio Shares Surge 6.6% Following Pfizer Patent Settlement
- Stock Surge: BridgeBio (BBIO) shares rose 6.6% following a court filing that disclosed a settlement in a patent case involving Pfizer's (PFE) Vyndamax drug, indicating market optimism regarding the company's future prospects.
- Pfizer Settlement Impact: Pfizer's agreement with Hikma to dismiss its lawsuit without prejudice may provide a favorable resolution for other patent disputes, further stabilizing its market position and potentially reducing litigation risks.
- Analyst Expectations: Barclays analyst Eliana Merle forecasts that the settlement could lead to generic Vyndamax entry by 2031, with BBIO shares potentially rising 30-40% in a favorable outcome scenario, while a loss could see a decline of 20-30%, highlighting the market's sensitivity to this event.
- Market Reaction: Pfizer's stock ticked up 0.8%, reflecting investor optimism about the positive developments in its patent litigation, which also supports the market potential for BridgeBio's Attruby drug in the heart disease sector.
See More
NASDAQ 100 Pre-Market Activity Overview
- Market Decline: The NASDAQ 100 pre-market indicator fell by 350.87 points to 26,954.81, indicating a bearish market sentiment that could impact investor confidence and subsequent trading decisions.
- NVIDIA Trading Activity: NVIDIA Corporation (NVDA) saw a drop of $7.56 to $209.05 with a trading volume of 10,044,906 shares, reflecting potential profit-taking after reaching a 52-week high in the previous session.
- ProShares UltraPro QQQ Performance: ProShares UltraPro QQQ (TQQQ) decreased by $2.66 to $59.98, with a volume of 7,002,488 shares, representing a 138.39% increase from its 52-week low, indicating strong market rebound interest in this ETF.
- Pfizer Earnings Expectations: Pfizer, Inc. (PFE) rose by $0.825 to $27.62 with a trading volume of 3,297,418 shares, and is expected to report earnings of $0.74 per share for March 2026, reflecting a 92% increase from last year, showcasing the company's robust profitability.
See More
Bristol Myers Squibb's Valuation Attractiveness Analysis
- Valuation Metrics Appeal: Bristol Myers Squibb (BMS) has a market cap of approximately $120 billion and a low forward P/E ratio of 9.4, significantly below the healthcare sector average of 17.3, indicating its attractiveness as a value investment, particularly for income-focused investors.
- Growth Prospects Challenges: While BMS's growth portfolio achieved a 17% sales increase in 2025, the expiration of patents for its top drugs, Eliquis and Opdivo, in 2028 is expected to significantly pressure future revenues, leading investors to adopt a cautious outlook on its growth potential.
- Dividend Appeal: With a forward dividend yield of 4.3% and a record of increasing dividends for 17 consecutive years, BMS remains attractive to income investors despite a lack of significant growth, helping to maintain investor confidence in the stock.
- Market Competition Analysis: Although BMS's valuation metrics are relatively low, Pfizer's forward P/E ratio stands at 9.1, indicating that there are other more attractive investment options in the market, and BMS needs to identify its unique value proposition to attract more investors.
See More
Valuation Analysis of Bristol Myers Squibb Stock
- Valuation Appeal: Bristol Myers Squibb (BMS) has a forward P/E ratio of 9.4, significantly lower than the healthcare sector average of 17.3, indicating its stock may attract value investors, especially with a market cap of around $120 billion.
- Growth Prospects Challenges: Despite BMS's appealing growth potential, the looming patent cliff poses a significant risk for revenue decline in the coming years, particularly as its top drugs, Eliquis and Opdivo, face patent expiration in 2028, which could severely impact total revenue.
- Dividend Attraction: With a forward dividend yield of 4.3% and a record of increasing dividends for 17 consecutive years, BMS remains attractive to income investors, who may prioritize steady cash flow over growth concerns.
- Competitor Comparison: Compared to competitors like Pfizer (PFE) and AbbVie, BMS's lower valuation may not be enough to offset the competitive pressure, as AbbVie appears more attractively valued when considering growth projections over the next five years.
See More
RELAY THERAPEUTICS INC SIGNS SUPPLY AGREEMENT WITH PFIZER FOR ATIRMOCICLIB IN PHASE 3 CLINICAL TRIAL
- Partnership Announcement: Relay Therapeutics has entered a supply agreement with Pfizer for the drug Atirmociclib.
- Clinical Trial Phase: The agreement is associated with a Phase 3 trial for Atirmociclib, indicating progress in its development.
See More
Pfizer Settles Patent Lawsuits with Generic Drug Makers
- Settlement Agreements: Pfizer has entered into settlement agreements with Dexcel Pharma, Hikma Pharmaceuticals, and Cipla Ltd, extending the patent expiry date for VYNDAMAX to June 1, 2031, which stabilizes expected revenues and mitigates the anticipated decline starting in 2029.
- Market Leadership: VYNDAMAX commands a 75% share of the ATTR-CM prescription market, being the only once-daily capsule approved for this condition, demonstrating significant reductions in all-cause mortality and cardiovascular-related hospitalizations, thereby reinforcing Pfizer's competitive edge.
- Enhanced Patient Care: Pfizer's decision to discontinue VYNDAQEL in the U.S. focuses on VYNDAMAX, aiming to improve patient convenience and adherence through a single daily capsule, particularly beneficial for patients with multiple concurrent conditions requiring various oral medications.
- Commitment to Innovation: Pfizer executives highlighted that the settlement outcome not only recognizes the value of innovative science but also underscores the company's unwavering commitment to ATTR-CM patients, which is expected to further enhance VYNDAMAX's market penetration and patient reach.
See More
BridgeBio Shares Surge 6.6% Following Pfizer Patent Settlement
- Stock Surge: BridgeBio (BBIO) shares rose 6.6% following a court filing that disclosed a settlement in a patent case involving Pfizer's (PFE) Vyndamax drug, indicating market optimism regarding the company's future prospects.
- Pfizer Settlement Impact: Pfizer's agreement with Hikma to dismiss its lawsuit without prejudice may provide a favorable resolution for other patent disputes, further stabilizing its market position and potentially reducing litigation risks.
- Analyst Expectations: Barclays analyst Eliana Merle forecasts that the settlement could lead to generic Vyndamax entry by 2031, with BBIO shares potentially rising 30-40% in a favorable outcome scenario, while a loss could see a decline of 20-30%, highlighting the market's sensitivity to this event.
- Market Reaction: Pfizer's stock ticked up 0.8%, reflecting investor optimism about the positive developments in its patent litigation, which also supports the market potential for BridgeBio's Attruby drug in the heart disease sector.
See More
NASDAQ 100 Pre-Market Activity Overview
- Market Decline: The NASDAQ 100 pre-market indicator fell by 350.87 points to 26,954.81, indicating a bearish market sentiment that could impact investor confidence and subsequent trading decisions.
- NVIDIA Trading Activity: NVIDIA Corporation (NVDA) saw a drop of $7.56 to $209.05 with a trading volume of 10,044,906 shares, reflecting potential profit-taking after reaching a 52-week high in the previous session.
- ProShares UltraPro QQQ Performance: ProShares UltraPro QQQ (TQQQ) decreased by $2.66 to $59.98, with a volume of 7,002,488 shares, representing a 138.39% increase from its 52-week low, indicating strong market rebound interest in this ETF.
- Pfizer Earnings Expectations: Pfizer, Inc. (PFE) rose by $0.825 to $27.62 with a trading volume of 3,297,418 shares, and is expected to report earnings of $0.74 per share for March 2026, reflecting a 92% increase from last year, showcasing the company's robust profitability.
See More
Bristol Myers Squibb's Valuation Attractiveness Analysis
- Valuation Metrics Appeal: Bristol Myers Squibb (BMS) has a market cap of approximately $120 billion and a low forward P/E ratio of 9.4, significantly below the healthcare sector average of 17.3, indicating its attractiveness as a value investment, particularly for income-focused investors.
- Growth Prospects Challenges: While BMS's growth portfolio achieved a 17% sales increase in 2025, the expiration of patents for its top drugs, Eliquis and Opdivo, in 2028 is expected to significantly pressure future revenues, leading investors to adopt a cautious outlook on its growth potential.
- Dividend Appeal: With a forward dividend yield of 4.3% and a record of increasing dividends for 17 consecutive years, BMS remains attractive to income investors despite a lack of significant growth, helping to maintain investor confidence in the stock.
- Market Competition Analysis: Although BMS's valuation metrics are relatively low, Pfizer's forward P/E ratio stands at 9.1, indicating that there are other more attractive investment options in the market, and BMS needs to identify its unique value proposition to attract more investors.
See More
Valuation Analysis of Bristol Myers Squibb Stock
- Valuation Appeal: Bristol Myers Squibb (BMS) has a forward P/E ratio of 9.4, significantly lower than the healthcare sector average of 17.3, indicating its stock may attract value investors, especially with a market cap of around $120 billion.
- Growth Prospects Challenges: Despite BMS's appealing growth potential, the looming patent cliff poses a significant risk for revenue decline in the coming years, particularly as its top drugs, Eliquis and Opdivo, face patent expiration in 2028, which could severely impact total revenue.
- Dividend Attraction: With a forward dividend yield of 4.3% and a record of increasing dividends for 17 consecutive years, BMS remains attractive to income investors, who may prioritize steady cash flow over growth concerns.
- Competitor Comparison: Compared to competitors like Pfizer (PFE) and AbbVie, BMS's lower valuation may not be enough to offset the competitive pressure, as AbbVie appears more attractively valued when considering growth projections over the next five years.
See More
RELAY THERAPEUTICS INC SIGNS SUPPLY AGREEMENT WITH PFIZER FOR ATIRMOCICLIB IN PHASE 3 CLINICAL TRIAL
- Partnership Announcement: Relay Therapeutics has entered a supply agreement with Pfizer for the drug Atirmociclib.
- Clinical Trial Phase: The agreement is associated with a Phase 3 trial for Atirmociclib, indicating progress in its development.
See More
